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Abstract 
 
There are currently numerous oncolytic viruses undergoing clinical trial evaluation in cancer 
patients and one agent,Talimogene laherparepvec, has been approved for the treatment of 
malignant melanoma. This progress highlights the huge clinical potential of this treatment 
modality, and the focus is now combining these agents with conventional anti-cancer 
treatments or agents that enhance viral replication, and thereby oncolysis, in the tumour 
microenvironment. We evaluated the combination of reovirus with rapamycin in B16F10 cell, 
a murine model of malignant melanoma, based on potential mechanisms by which mTOR 
inhibitors might enhance viral oncolysis. Rapamycin was not immunomodulatory in that it 
had no effect on the generation of an anti-reovirus neutralising antibody response in 
C57/black 6 mice. The cell cycle effects of reovirus (increase G0/G1 fraction) were 
unaffected by concomitant or sequential exposure of rapamycin, However, rapamycin 
attenuated viral replication if given prior or concomitantly with reovirus and similarly reduced 
reovirus-induced apoptotic cell death annexin V/PI and caspase 3/7 activation studies. We 
found clear evidence of synergistic antitumour effects of the combination both in vitro and in 
vivo, which was sequence dependent only in the in vitro setting. In conclusion, we have 
demonstrated synergistic anti-tumour efficacy of reovirus and rapamycin combination.  
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Introduction 
 
There has been considerable interest in the development of oncolytic viruses as anticancer 
agents1. A number of viruses have now been studied in the pre-clinical and clinical setting2, 
with an oncolytic herpesvirus Talimogene laherparepvec now approved for the treatment of 
malignant melanoma3. However, the full potential of these agents will be in combination 
therapies, with indications of this from studies combining OV with cytotoxic agents, targeted 
therapy, radiotherapy and immune checkpoint inhibitors (reviewed recently in Choi et al. 
2016).  Reovirus is a double-stranded RNA virus that is ubiquitious in the environment and is 
not associated with any known disease in humans5. It has been shown to be oncolytic in a 
broad range of cancer cell lines6-9, though the exact mechanism of this selective activity has 
yet to be fully determined. Activation of the Ras pathway in transformed cells, or their 
upstream or downstream elements, is an important factor in a cell’s permissiveness to 
reovirus oncolysis10. This is in part due to the inability of Ras-activated cells to phosphorylate 
cellular PKR, but also due to enhancement of virus uncoating, particle infectivity and 
apoptosis-dependent release11.  
 
Tumour regression after intratumoral and systemic delivery of reovirus has been reported in 
both immunodeficient and immunocompetent murine models10, 12. Several clinical studies 
have now been completed using both intratumoral and systemic delivery of reovirus13, 14. 
These have confirmed that reovirus is safe, with only mild flu-like symptoms, and that 
reoviral infection of metastatic tumour deposits occurs when delivered systemically. 
However, while there was evidence of antitumor activity in patients with advanced cancers 
(recently reviewed in Gong et al., 2016 ) further strategies are clearly necessary for reovirus 
to become a useful anticancer agent  
Rapamycin is an inhibitor of the Serine/Threonine protein kinase mTOR (mammalian target 
of rapamycin), which regulates cell growth and metabolism in response to environmental 
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cues. Rapamycin and its analogues bind FK506 binding-protein, which in turn binds to 
mTOR leading to the inhibition of downstream signalling. Rapamycin induces autophagy and 
causes cell cycle arrest in tumour cells, but also inhibits endothelial cell proliferation, hypoxia 
induced factor-1 (HIF-1), expression of vascular epithelial growth factor (VEGF), tumour-
associated angiogenesis, and vascular permeability16, 17.  These vascular effects of mTOR 
inhibitors, together with their direct anti-tumour and immunosuppressive affects, 
demonstrate the potential of these drugs as anticancer agents. A number of mTOR inhibitors 
have shown benefit in the treatment of cancers and are now in clinical use18-20. mTOR 
inhibitors are cytostatic and consequently there has been interest in combining them with 
other treatment modalities. Rapamycin has been shown to act synergistically with a number 
of chemotherapeutic agents21-22, radiotherapy23 and endocrine treatment24. Synergistic 
antitumour effects of rapamycin and oncolytic adenoviruses have been reported25, 26 In this 
study, we have assessed the combination of rapamycin with reovirus in a murine melanoma 
model for therapeutically useful synergistic tumour kill. The potential mechanisms behind 
these interactions were also investigated.   
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Materials and Methods 
 
Cell lines 
The mouse melanoma cell line B16.F10 was cultured in Dulbecco’s Modified Eagle’s 
Medium (DMEM; Sigma) at 37oC and 10% CO2. L929, a murine fibroblast-like line, was 
cultured in DMEM at 37oC and 5% CO2. Both cell lines were bought from ATCC. All media 
were supplemented with 2mM GlutaMAX-1 supplement (Invitrogen), 100 units/ml 
penicillin/streptomycin (Sigma) and either 10% (v/v) foetal calf serum (FCS) for routine 
passage or 2% (v/v) FCS for reovirus infection work.  Mycoplasma testing was routinely 
carried out once a month using MycoAlert PLUS detection kit (Lonza, LT07-710) 
 
Reovirus stock and chemotherapeutic agents 
Reovirus type 3 Dearing strain Reolysin® was obtained from Oncolytics Biotech. Inc. 
(Calgary, Canada). Virus stock titre and virus stability was measured by standard plaque 
assay of serially diluted samples on L929 cells. Six-well plates were seeded with 1 x 106 
L929 cells per well and infected with dilutions of viral stocks. After 3h incubation at 37oC, the 
virus inoculum was removed and the wells were overlaid with a 1:1 mixture of 2% 
SeaPlaque agarose (Cambrex Bio Science Rockland, Inc, ME) and 2 x MEM (Invitrogen) 
supplemented to a final concentration of 5% (v/v) FCS, 100 units/ml penicillin/streptomycin 
and 2mM GlutaMAX-1. Wells were stained with 500µL 0.03% neutral red (Sigma) in PBS 
72h post-infection and plaques were counted 3 to 4 h later. Rapamycin was purchased from 
Sigma. 
 
In vitro survival and synergy assays 
B16.F10 cells were plated in 96-well plates at a density of 7.5 x 103 cells per well. After 24 
hours, they were infected with known dilutions of reovirus or rapamycin, either alone, 
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concomitantly or in sequence, and after 48h incubation, cell viability was quantified using the 
CellTiter 96 AQueous One Solution Cell Proliferation Assay reagent 3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS; Promega) 
according to manufacturer’s instructions. Briefly, 20µL of MTS reagent was added to each 
well and following incubation at 37oC for 1-4 hours, absorbance was measured at 495nm. 
Survival was calculated as a percentage compared to untreated cells and the median 
effective dose (ED50) was determined. 
 
The effect of the combination of reovirus and rapamycin on B16.F10 cell viability was 
assessed. Experiments were performed as described above using 4, 2, 1, 0.5 and 0.25 
times the calculated ED50 of each agent in a constant ratio checkerboard design. The 
agents were applied either concomitantly or sequentially with a 24h interval and survival was 
assessed 48h after the first agent was applied. 
 
CalcuSyn software (Biosoft, Ferguson, MO) was used to calculate combination-index (CI) 
values. Derived from the median-effect principle of Chou and Talalay27, the CI provides a 
quantitative measure of the degree of interaction between two or more agents. A CI of 1 
denotes an additive interaction, >1 antagonism and <1 synergy. 
 
Virus recovery from in vitro cultures 
The effect of rapamycin on viral replication in vitro was assessed. Flasks seeded with 
B16.F10 cells were exposed to reovirus alone, concomitant reovirus and rapamycin, 
rapamycin followed 24 hours later by reovirus, and reovirus followed 24 hours later by 
rapamycin. After 48 or 72 hours the flasks were transferred to a -80°C freezer and the virus 
titre in the resulting lysate was determined by plaque assay as described above. 
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Determination of apoptosis induction by Annexin V / PI staining 
Following overnight seeding, B16.F10 cells were exposed to reovirus and rapamycin as 
single agents or in combination and 72 hours later the percentage of early and late apoptotic 
cells was estimated by flow cytometry. Adherent and non-adherent cells were collected, 
washed in cold PBS, re-suspended at 1 x 106 in 500µL PBS and then incubated for 15 min 
at room temperature, in the dark, in cold 1 x binding buffer containing Annexin V-FITC 
antibody, according to manufacturer’s instructions (Merck Biosciences Ltd). The cells were 
pelleted and re-suspended in cold 1 x binding buffer. Cells were stained with 10µL propidium 
iodide (PI) at 30µg/mL and analysed by flow cytometry using a MACSQuant Analyser 
(Miltenyi Biotech Ltd), and MACSQuantify software (Miltenyi Biotech Ltd). 
 
Determination of apoptosis induction by Caspase 3/7 activation 
B16.F10 cells were exposed to reovirus and rapamycin as single agents or in combination 
as decribed above and 72 hours later caspase 3/7 activation was measured using the 
CaspaseGlo assay (Promega). At the time point of interest, 100l of CaspaseGlo was added 
to each well and the plate shaken to ensure adequate mixing. The plate was incubated at 
room temperature for 1 hour and then the luminescence measured at 565nM using a 
Beckman Coulter plate reader.  
 
Cell cycle analysis of B16.F10 cells exposed to reovirus and/or rapamycin  
 
B16.F10 cells were plated and incubated at 370C overnight. Cells were infected with 
Reovirus at MOI of 10 and 10nM Rapamycin (Sigma). The treated B16.f10 cells were 
trypsinised and washed in ice cold PBS. The cells were centrifuged at 1500rpm at 40C for 
3min and resuspended in 300ul of ice cold 50% FCS/PBS. 900ul of ice cold 70% ethanol 
was added drop wise during vortexing. The resulting cell suspend was incubated overnight 
at 40C. The cells were washed twice with ice cold PBS cells. The pellet was resuspended in 
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200ul of 5µg/ml propidium iodide and 1mg/ml Ribonuclease and incubated at 370C for 30 
min in the dark. Analysis was carried out by flow cytometry using a MACSQuant Analyser 
(Miltenyi Biotech, Bergisch Gladbach, Germany) and MACSQuantify software (Miltenyi 
Biotech). 
 
Autophagy Analysis 
B16.F10 cell were seeded at 5x105 cells/well and incubated overnight at 37ºC. Cells were 
then treated with either medium with 10% FCS, 10nM rapamycin, reovirus MOI 10, or a 
combination of rapamycin 10nM and reovirus MOI 10 either concomitantly or in sequence 
with 24 intervals per treatment. After 48 hours, cells were trypsinised with StemPro® 
Accutase (Thermo Fisher) and then washed 3x with 1x assay buffer (Enzo). Each sample 
was then resuspended in 250µl of 1x assay buffer 5% FBS. Cyto-ID® stain (Enzo) was 
diluted 1:1000 in 1x assay buffer and 250µl was then added to each sample, and then 
incubated for 30 minutes at 37ºC. Cells were then washed 3x with 1x assay buffer and were 
resuspended in 500µl 1x assay buffer before being analysed on a MACSQuant® Analyzer 10 
(Miltenyi Biotec).    
 
PI3K-mTOR signalling cascade analysis 
B16.F10 cells were prepared the same way as the autophagy analysis samples, in terms of 
reovirus MOI, rapamycin concentration and term points. After 48 hours, cells were 
trypsinised with StemPro® Accutase (Thermo Fisher) and then washed. The cells were then 
fixed and permeabilizated using the FlowCellect PI3K-mTOR signalling cascade mapping kit 
(Millipore FCCS025210 | FlowCellect™ PI3K-mTOR Signaling Cascade kit). Resulting cells 
were stained with Anti-phospho-Ribosomal Protein S6 (Ser235) PerCP conjugate 
Monoclonal Antibody and Antiphospho-Akt1/PKBα (Ser473) Alexa Fluor 488 conjugate 
Monoclonal Antibody (Millipore kit as above). Cells were then washed with 1x assay buffer 
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and were resuspended in assay buffer before being analysed on a MACSQuant® Analyzer 
10 (Miltenyi Biotec). 
In vivo studies 
All procedures were approved by the United Kingdom Home Office and University of Surrey 
AWERB. The design of individual experiments will generally involve obtaining maximal 
information from the minimum resources. Sample sizes will be set using power analysis and 
calculated using Graph StateMate. Female C57Bl/6 mice (5-6 weeks old) (were purchased 
from B and K Universal Ltd and all animal experiments were repeated at least three times. 
Subcutaneous tumours were established on the flank of each mouse by injecting 5 x 105 
cells in a volume of 100µL Hanks Balanced Salt Solution (HBSS; Sigma). Animals were 
examined thrice weekly for tumour development. Three orthogonal tumour diameters (d1, d2, 
and d3) were measured using Vernier callipers and tumour
 volume was calculated from the 
formula V =(length x width)/2 . Animals were killed when tumour size exceeded 15mm in any 
one dimension. Reovirus was administered intratumorally as described previously28.  
 
Once tumours were established, (average tumour diameter 4.5-5.5mm, approximately 10-12 
days), mice were randomly assigned to five treatment groups: (a) HBSS 100µL 
intraperitoneal (i.p.) control, (b) reovirus 3 x 108 pfu reovirus in 100µL volume intratumourally 
on day 1 and day 4, (c) 5mg/kg of rapamycin i.p. alone, or (d) concomitantly with rapamycin 
on day1 and 4, or (e) 24h after reovirus on day 2 and 5. All animals receiving rapmycin had 
further i.p. rapamycin on day 8 and 11 (N=8 per group) . 
 
Viral recovery from tumours 
Tumours were established in mice as described above. Following random assignment to 
treatment groups, mice received either 3 x 108 pfu reovirus in 100µL volume intratumourally 
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alone, concomitant reovirus and 5mg/kg of rapamycin, or reovirus followed 24h later by 
rapamycin.  
 
Mice were sacrificed 4 days after commencement of treatment and tumours, livers, lungs 
and hearts excised. Tumour and organs were weighed and homogenized in a TissueLyser 
(Qiagen) at 30 Hz for 2 min. Following centrifugation to clarify the virus lysate, virus titre was 
determined by plaque assay on L929 cells as described above and expressed as pfu/g 
tissue.  
Serum analysis for presence of neutralising antireoviral antibodies. 
The methodology used for analysis of neutralising antireovirus antibody (NARA) has been 
reported recently29. Briefly, serum samples collected from individual mouse groups on day 4 
after treatment were batched and analyzed simultaneously. To determine a suitable virus 
dilution for subsequent assay, L929 cells were plated in 96-well plates at 2.5 × 104 per well 
and incubated overnight at 37°C and 5% CO2. Reovirus stock (3.5 × 10
10/mL) was added in 
two dilution series (2- and 10-fold) across the plate such that the final dilutions of the two 
series were 1:32,768 and 1:1012. After 2 h, the reovirus inoculum was removed and 
replaced with growth medium. After a further 48 h, cell survival was measured by MTT 
assay. To establish a suitable dilution series for the estimation of neutralising antibody levels 
in the serum, the above experiment was repeated with a constant titre of reovirus (known to 
cause 80% cell death) that was preincubated with a dilution series of goat polyclonal 
antireoviral antibody, and cell survival was measured at 48 h by MTT assay. 
 
Statistical analysis 
Statistical analysis was performed using GraphPad Prism 4 (GraphPad Software Inc.). 
Comparisons between groups were done using the t test and of variance (ANOVA) models. 
Survival curves were generated using the Kaplan-Meier method. In vivo survival data was 
analysed using the logrank test. 
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Results 
Concomitant Reovirus and Rapamycin is antagonistic in B16.F10 Cells 
To determine the effect of reovirus and rapamycin on the mouse melanoma cell line, 
B16.F10, cell viability was first assessed after 48 hours of exposure to each agent, using the 
MTS assay. B16.F10 was found to be permissive to reovirus with a medium effective dose 
(ED50) between 1 and 5 MOI (figure 1). Heat inactivated reovirus had no effect on B16F10 
cells (data not shown). Rapamycin also decreased cell viability with an ED50 between 1nM 
and 5nM. Previous reports have demonstrated synergistic anti-tumour effects of rapamycin 
and chemotherapy combinations30. All cells were assessed for viability by MTS assay, 48 
hours after the first treatment was given. Having established the ED50s, rapamycin and 
reovirus were then combined at 0.25, 0.5, 1, 2, 4 times the ED50 of each agent using a 
constant ratio chequerboard design. The effect of rapamycin and reovirus on cell viability 
was reproducible with less than 0.01% chance of randomly observing an effect of this large 
with an experiment of this size (2-way ANOVA; p<0.0001). Bonferroni post-tests showed no 
significant difference between the means at each dose level for single agent and 
combination treatment. The effect of the combination of reovirus and rapamycin on cell 
viability was assessed by isobologram analysis and the calculation of combination indices 
(CI). With the concomitant administration of reovirus and rapamycin there was evidence of 
antagonism with a combination index at ED50, ED75, and ED90, of 1.6, 1.7 and 2.6 
respectively (figure 2). 
 
Cytotoxicity is affected by the sequence of combination treatment  
Given that synergy with rapamycin is sequence dependent with certain chemotherapeutic 
agents30, we wanted to evaluate the effect of the sequence of reovirus and rapamycin on cell 
viability. Cells were plated on 96-well plates and exposed to rapamycin, reovirus or a 
combination as described earlier. However, two further groups were added: reovirus 
followed 24 hours later by rapamycin, and rapamycin followed 24 hours later by reovirus. 
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The 24 hour time point was used following a report of optimal cell kill when an mTOR 
inhibitor was given 24 hours after paclitaxel30 in a breast cancer model. All cells were 
assessed for viability by MTS assay, 48 hours after the first treatment was given. Once 
again the experiments were reproducible, with a significant difference between the 
treatments using 2-way ANOVA (p<0.0001). When rapamycin was given before reovirus 
there was no difference between the means at each dose level between that of reovirus or 
rapamycin alone. However, when rapamycin was given after reovirus there was a significant 
difference between the means at each dose level compared with either agent alone 
(p<0.001). Also, the combination of rapamycin and reovirus was found to be synergistic by 
isobologram analysis only when reovirus was followed by rapamycin, with a CI value of 0.5, 
0.4, and 0.4 for the ED50, ED75 and ED90 respectively. When rapamycin was given before 
reovirus there was similar evidence of antagonism as seen with concomitant treatment with 
a CI value of 1.3, 1.9, and 2.7 for the ED50, ED75 and ED90 respectively (Figures 1 and 2). 
 
The effect of reovirus, rapamycin or combination on cell cycle.  
B16F10 cells were exposed to reovirus, rapamycin, both concomitantly or in sequence.  For 
comparison, NIH3T3 cells were similarly exposed in the same permutations. In NIH3T3 cell, 
rapamycin exposure led to increased G0/G1 fraction and marked lowering of G2/M and S 
phase fractions which was unaffected by the later addition of reovirus. Reovirus exposure 
also resulted in reduction in G2/M and S phase, but to a lesser extent than with rapamycin, 
and this reduction was largely unaffected by the concomitant or sequential exposure to 
rapamycin.  In B16 F10, the effects of all treatment permutations resulted in more marked 
increases in G0/G1 fraction, and more marked reduction in G2/M and S phase fractions. The 
highest reduction in G2/M and S phase fractions associated with rapamycin were similar to 
NIH3T3 cells where the effects of reovirus were not overcome by rapamycin in the 
combination groups (figure 3). 
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Concomitant reovirus and rapamycin shuts down viral production 
The effect of rapamycin on viral replication was assessed by plaque assay. Flasks seeded 
with B16.F10 cells were exposed to reovirus alone, concomitant reovirus and rapamycin, 
rapamycin followed 24 hours later by reovirus, and reovirus followed 24 hours later by 
rapamycin. After 48 or 72 hours, the flasks were transferred to a -80°C freezer and the 
resulting supernatant serially diluted and allowed to transfect L929 cells before an overlay 
was added. 
Both pre-treatment with rapamycin, or concomitant reovirus and rapamycin treatment, 
significantly reduced the number of plaques (Bonferroni post-test; p<0.001) (figure 4). 
However, when reovirus preceded rapamycin there was no significant difference in plaque 
number compared to reovirus alone (Bonferroni post-test; p<0.001). These results indicate 
that rapamycin inhibits viral replication when given together or prior to reovirus but that this 
effect is lost if rapamycin is given after the reovirus exposure. Significantly more plaques 
were seen at 72 hours than 48 hours, but the difference between the treatment groups 
remained the same indicating that the effect of rapamycin on reovirus persists over this 
additional time period (figure 4).  
B16F10 cell apoptosis is reduced with concomitant administration of reovirus and 
rapamycin 
 
To assess the contribution of apoptosis to the mechanism of cell death with the combination 
of reovirus and rapamycin, two apoptosis assays were used.  
Using the Annexin V/PI assay, the difference in the percentage of early apoptotic cells 
between treatments was significant (1-way ANOVA; p<0.001). Bonferroni’s multiple 
comparison test showed there was a significant reduction in the percentage of early 
apoptotic cells when rapamycin was given prior to, or concomitantly with, reovirus (p<0.05). 
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However, when rapamycin was sequenced after reovirus there was no significant difference 
compared with reovirus alone (figure 5).  
 
Caspase-3/7 is a recognised marker of apoptotic induction inside cells. The presence of 
activated caspase-3/7 suggests a cell that is proceeding towards a terminal pathway of cell 
death. Caspase-3 is an ‘executioner’ caspase whose activation leads to the cleavage of a 
wide range of proteins including PARP and ICAD in the downstream events during 
apoptosis. Treatment with reovirus alone led to a significant increase in caspase 3/7 
activation compared with untreated cells (1-way ANOVA). As seen with the Annexin V / PI 
assay, when rapamycin was used as a single agent, or before or concomitantly with reovirus 
there was a reduction in the activation of caspase 3/7 (p<0.001). However, when reovirus 
infection preceded rapamycin treatment there was no significant difference in caspase 3/7 
activation compared to reovirus treatment alone (figure 5).  
 
Assessment of the effect of combination treatment on cell signalling. 
To determine the effect of reovirus on mTOR pathway signalling with concomitant or 
sequential treatment of B16F10 cells a flow cytometry based assay was performed (figure 
6). Focusing on the PI3K-mTOR signalling cascade we looked for changes in the levels of 
phosphorylated-Akt (p-Akt) above mTOR and the phosphorylated-ribosomal S6 protein 
(p70S6K) downstream of mTOR. Reovirus infection alone resulted in a marked increase in 
p70S6K expression. In contrast B16.F10 cells treated with rapamycin alone, showed a large 
decrease in phosphorylation of ribosomal protein S6 with only a slight effecting on the 
phosphorylation of AKT. All combinations of rapamycin and reovirus showed similar results 
as rapamycin alone. Which suggest that rapamycin has the most dominant effect on the 
PI3K-mTOR signalling pathway.  
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Reovirus inhibits Rapamycin induced autophagy 
Rapamycin is also an inducer of autophagy, as inhibition of mTOR mimics cellular starvation 
by blocking signals required for cell growth and proliferation. We investigated whether 
induction of autophagy by rapamycin was influenced by the pro-apoptotic effects of reovirus. 
Induction of autophagy was assessed through detection of autophagic vacuoles using a 
cytoplasmic dye in a flow cytometric assay. Cells treated with 10nM of rapamycin (Figure 7b) 
caused a rapid increase in autophagy when compared to control cells (Figure 7a), but cells 
treated with reovirus MOI 10, Figure 7c, exhibited a less dramatic increase in autophagy. 
Sequential treatment with reovirus then rapamycin, Figure 7d, and rapamycin then reovirus, 
Figure 7e, resulted in significantly different levels of autophagy. Cells treated with reovirus 
before rapamycin had autophagy levels similar to cells treated with reovirus alone, and when 
the treatment sequence was reversed, autophagy levels were similar to rapamycin alone. 
When cells were treated with both agents concomitantly, figure 7f, autophagy levels was 
similar to treatment with reovirus alone. These results indicate that the reovirus dictated the 
mode of cell death when combined concomitantly with rapamycin. 
Combined reovirus and rapamycin treatment enhances tumour growth delay and 
prolongs survival in a mouse melanoma model 
 
The in vivo effects of reovirus, rapamycin and their combination were assessed in a mouse 
melanoma model using B16.F10 cells in C57/BL6 mice. Cells were implanted 
subcutaneously in the flank of the mice and treated when they had reached an average 
diameter of 4.5-5.5mm, usually 10 days after implantation. Mice were then treated with 
intratumoural reovirus, intraperitoneal rapamycin, or both, as described earlier. There were 
no obvious toxic effects of either single agent or combination treatments and experiments 
were concluded if tumour growth exceeded 15mm in any one dimension or there was 
ulceration of the tumour.  
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Both rapamycin and reovirus alone resulted in a significant reduction in tumour growth 
compared to control (2-way ANOVA p<0.0001), however the combination of the two, 
whether concomitant or in sequence, resulted in the most effective growth delay (figure 8). 
The median survival for the control, rapamycin, reovirus, sequence, and concomitant groups 
was 8, 11, 14, 15, and 17 days respectively. There was no significant difference in median 
survival between concomitant and sequenced treatment, and the difference between 
sequenced treatment and reovirus alone did not reach significance either. However, the 
difference in survival between the concomitant group and reovirus alone did reach 
significance (Log-rank test; p=0.02).  
Viral replication in tumour and organs of treated mice 
To assess the effect of rapamycin on reoviral replication in vivo, we evaluated viral 
replication in tumours and organs 4 days after treatment with either reovirus alone, 
concomitant reovirus and rapamycin, or reovirus followed 24 hours later by rapamycin. 
Following sacrifice, viral titres were determined in tumour and organs using plaque assays 
as described early. As expected, the highest viral yield was in the resected tumour, the liver 
harboured the most reovirus of all the organs evaluated. There was no difference in virus 
titre in the lung, liver or heart between the treatment groups. There was, however, a 
difference in the viral titre in the resected tumours with a significant increase in virus seen in 
the sequenced group compared to the reovirus alone group (unpaired t-test; p=0.03). There 
was no significant difference between the sequence or concomitant groups and neither was 
there a difference between the concomitant and reovirus alone groups (figure 9). 
Neutralising anti-reoviral antibody levels are not reduced by the rapamycin 
Rapamycin is known to have immunosuppressive properties. The combination of other 
immunosuppressive agents with reovirus has been shown to reduce the humoral response 
and improve the antitumour effects of reovirus31. Similarly, other oncolytic viruses have 
18 
 
shown improved efficacy in combination with immunosuppressive agents23, 33. To determine 
whether the administration of rapamycin affected the anti-reovirus humoral response, we 
assessed the NARA response to reovirus and the reovirus/rapamycin combination, both 
concomitant and sequential, in C57BL/6 mice. Using a previously reported assay29, we 
found that, at the dose of 5mg/kg, rapamycin had no significant effect on the NARA 
response whether given concomitantly or sequentially (Figure 10). 
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Discussion 
 
Reovirus is a wild-type oncolytic virus that has activity in a broad range of cancers. It has 
been shown to be safe and tolerable when given both by intratumoural and intravenous 
injection14, 34 While responses have been seen with reovirus alone in patients with advanced 
malignancies the current focus is on combining reovirus with other treatments to try and 
improve efficacy35 
In this study we assessed the combination of reovirus with the mTOR inhibitor rapamycin in 
a conventional immunocompetent murine melanoma model. Malignant melanoma is 
increasing in incidence and despite key developments in targeted therapies and immune 
checkpoint inhibitor antibody therapy36, the majority of patients with metastatic disease still 
progress and die from their disease in a short period of time. There is therefore still an 
urgent need for novel treatment strategies for this disease.  
 
The mTOR inhibitors have been shown to have anticancer activity and are now in use in the 
clinical setting in patients with advanced renal cell carcinoma and in combination with 
aromatase inhibitors in breast cancer. The Akt-mTOR pathway is upregulated in up to 70% 
of malignant melanomas37. While there is some preclinical evidence of efficacy in melanoma 
models38, a phase II trial of single agent rapamycin in metastatic malignant melanoma was 
disappointing with only one objective response in 34 patients39. However, the combination of 
mTOR inhibitors with both conventional and novel therapies has been shown to improve 
response rates in pre-clinical21, 38-41  and clinical studies42.   
 
Three different oncolytic viruses have been combined with mTOR inhibitors 43,44 and all 
demonstrated synergistic anti-tumour effects in combination, with different hypotheses given 
for how the agents interact to increase cancer cell death. The potential mechanisms by 
which mTOR inhibitors might enhance viral oncolysis include targeting of alternative 
signalling pathways, suppression of the antiviral immune response, and alteration in tumour 
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vasculature through their antiangiogenic properties. Furthermore. mTOR inhibitor induced 
autophagy may generate decomposed cellular molecules as nutrients to support viral 
replication. 
 
In this study, we assessed the novel combination of reovirus and rapamycin and also found 
evidence of synergistic anti-tumour cytotoxicity. However, at least in vitro, this synergy 
appeared to be sequence dependent with the combination being antagonistic unless 
reovirus is given prior to rapamycin. Rapamycin is known to act as a cytostatic agent, being 
a potent inducer of G1 cell cycle arrest. This may explain the antagonism seen in cells 
exposed to rapamycin before or concomitantly with reovirus, as we have previously reported 
that reovirus oncolysis is cell cycle dependent, occurring in S phase46. However, we have 
also shown that pre- or concomitant treatment with rapamycin shuts down reovirus 
replication, as determined by viral plaque assay, which could account for the antagonism 
seen with these combinations. It would also explain the reduction in apoptosis seen after 
pre- and concomitant treatment with rapamycin. Rapamycin is known to increase myxoma 
virus replication in certain cancer cell lines47 in vitro. However, this is thought to be due to 
rapamycin-induced Akt activation, and the increased tropism of myxoma virus to cells with 
hyperactivation of Akt. Reovirus tropism is intimately related to the Ras pathway and there is 
now evidence that inhibition of mTORC1 leads to Ras/MAPK pathway activation48. 
Increasing activated S6 kinase levels lead to PI3K inhibition, via a negative feedback loop, 
leading to a reduction in Ras/MAPK signalling. A similar feedback loop can lead to Akt 
activation in certain cell lines5. In our study, we observed that reovirus exposure increases 
pS6 phosphorylation and slight increase p-AKT.  
 
Though a cytostatic agent, rapamycin has also been shown to induce apoptosis in cells 
lacking functional p5349-52. In our model, rapamycin reduced induced autophagy and reduced 
apoptosis in B16.F10 cells compared to untreated controls, whereas reovirus induced 
apoptosis, as has been demonstrated previously26. The shutdown in reoviral replication and 
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subsequent reduction in apoptosis and autophagy may explain this antagonism. Reovirus 
also induced autophagy in B16.F10 cells to a small extent but the dominant effect on the 
tumour cells was through reovirus where pre- or concomitant treatment with reovirus 
markedly reduced the pro-autophagy effect of rapamycin. However, this may be a cell 
specific phenomenon as a previous study showed a reduction in lung metastases after 
rapamycin treatment in a B16 mouse melanoma model reported no evidence of 
autophagy38. In the in vivo experiments, both single agent alone, and combination of 
rapamycin and reovirus resulted in a significant reduction in tumour growth and median 
survival. Combination treatment was significantly more effective than either treatment alone, 
however, unlike in the in vitro setting, there was no significant difference between 
concomitant and sequenced treatment. This may simply reflect the difference in treatment 
delivery, with the reovirus given intratumourally and the rapamycin via the peritoneum. One 
possibility for the synergy seen in other oncolytic virus models may be due to a reduction in 
the NARA response caused by rapamycin. Rapamycin as an immunosuppressant could 
potentially have an effect of reducing host immune response to viral infection. However, we 
found no significant attenuation in the NARA response, which may reflect differences in the 
dose scheduling of rapamycin or the timing of NARA assessment after viral administration. It 
is also possible that attenuation of the immune response may reduce the efficacy of 
reovirus-induced immune priming53. Rapamycin reduces the interferon responses to viral 
infection54, but also suppresses T-cell function55. This suppression not only effects T-
regulatory cells, which maybe undesirable, but also T-cell mediated viral responses which 
may actually improve reovirus infection. 
 
The mTOR pathway is considered a key regulator of cell metabolism, and rapamycin has 
been reported to elicit paradoxical effects on glucose metabolism and oxidative 
phosphorylation. The stimulatory or inhibitory effect on metabolism depends most likely on 
the nature of the dysregulation of cell signalling in tumour cells, so in turn, virus replication 
may be enhanced or inhibited in combination exposure in tumour cells56,57 
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Another possible mechanism of synergy is the effect of rapamycin on the tumour blood 
supply. Alteration of the tumour vasculature due to antiangiogenic therapy such as 
rapamycin can lead to a ‘normalisation window’ whereby disorganised blood vessels 
transiently reorganise56, reducing hydrostatic barriers to virus delivery. The subsequent 
withdrawal of rapamycin could then trap the virus within the tumour, as has been 
hypothesised in a colorectal mouse model combining adenovirus with the mTOR inhibitor, 
everolimus. While this model confirmed ablation of the primary antibody response with 
everolimus in immunocompetent mice, synergy was also seen in an immunosuppressed 
xenograft model. The authors argued that the withdrawal of regular mTOR inhibitor causes 
vascular disruption trapping the virus and facilitating viral spread within the tumour.  
In this study, we have demonstrated that the combination of reovirus with the mTOR 
inhibitor, rapamycin, is synergistic in a mouse melanoma model. While this appears to be 
sequence dependent in vitro, concomitant administration significantly improves survival in 
vivo. The mechanism for this synergy is uncertain though attenuation of the humoral 
response was not demonstrated. The combination of reovirus with other anticancer agents is 
currently being investigated in phase I and II trials.  
In conclusion, combination of rapamycin may enhance the therapeutic potential of oncolytic 
reovirus through number of mechanisms. This combination warrants clinical evaluation. 
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Figure Legends 
 
Figure 1. Rapamycin enhances reovirus cytotoxicity in a sequence dependent manner 
 Cells were exposed to rapamycin and reovirus at 0.25, 0.5, 1, 2, 4 x calculated ED50 for 
given exposure time and combined as follows: A, rapamycin followed 24 hours later by 
reovirus. B, concomitant rapamycin and reovirus. C, reovirus followed 24 hours later by 
rapamycin. 48 hours after exposure to first drug, cell viability was assessed using the MTS 
assay. 
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Figure 2. Sequence of reovirus then rapamycin is synergistic 
The classic isobologram for the sequenced combination of reovirus followed by rapamycin 
shows synergy at all effective dose levels (observed ED50, ED75, ED90 lie to the left of their 
respective hypothenuse).  
Combination Indices were generated using Calcusyn software. Data is presented as 
combination index value ± standard error of the mean at the effective dose indicated. 
Synergy was only seen when rapamycin was given 24 hours after reovirus.  
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Figure 3. The effect of reovirus and/or rapamycin on cell cycle. Rapamycin exposure 
results in most marked reduction of G2/M and S phase fractions. In both NIH3T3 cells and 
B16F10 cells, prior or concomitant exposure to reovirus reduces this effect. 
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Figure 4. Rapamycin shuts down viral replication 
Plaque assays were performed in 6 well plates using a L929 cell monolayer. B16.F10 cells 
were infected with reovirus with or without rapamycin, concomitantly or in sequence. Serial 
dilutions, 10-4 to 10-9, of resulting supernatant at 48 or 72 hours were prepared. Rapamycin 
reduces reovirus replication when given before or concomitantly with reovirus. Rapamycin 
given after reovirus does not effect reovirus replication. 
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Figure 5. Reovirus-induced apoptosis is reduced by pre- or concomitant treatment 
with rapamycin, as determined by Annexin/PI staining by FACS analysis (top), and 
Caspase 3 activation using CaspaseGlo Assay (bottom) 
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Figure 6. Assessment of the effect of combination treatment on cell signalling of the 
mTOR pathway by Flow based assay. A: Untreated B16.f10 B: Reovirus was added and 
incubated for 48 hrs. C: Rapamycin was added and incubated for 48 hrs.D: Reovirus was 
added for 24 hrs then removed and rapamycin added for 24 hrs. E: Rapamycin was added 
for 24 hrs then removed and reovirus added for another 24 hrs. F: Both reovirus and 
rapamycin were added and incubated for 48 hrs. 
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Figure 7: Autophagy levels were determined via Cyto-ID staining with FACs analysis. 
Cells were treated with either A) media 10% FBS, B) 10nM of rapamycin for 48 hours, C) 
Reo MOI 10 for 48 hours, D) Reo MOI 10 for 24 hours then rapamycin 10nM for 24 hours, E) 
rapamycin 10nM for 24 hours the Reo MOI 10 for 24 hours or F) Reo MOI 10 and rapamycin 
10nM for 48 hours concomitantly. FACs plots gated on autophagy positive cells.  
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Figure 8. Combination of reovirus and rapamycin reduces tumour growth and 
improves survival in mouse melanoma model 
C57Bl/6 mice (N=8) with a B16.F10 flank tumour were treated with i.t. reovirus (days 1 and 
4), i.p. rapamycin (days 1, 4, 8,and 11), or a combination (concomitant or with rapamycin 
24hrs after reovirus). Growth was expressed as tumour volume relative to volume at 
commencement of treatment. Concomitant treatment led to significantly slower tumour 
growth compared to either agent alone and a significant improvement in survival compared 
to reovirus or rapamycin alone (log-rank test; p0.02). There was no significant difference 
between combination treatment given in sequence or concomitantly.  
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Figure 9. B16.F10 tumours were seeded on the flanks of C57Bl/6 mice. Mice were 
treated with reovirus i.t. either alone or in combination with i.p rapamycin on days 1 or 2, 
viral titre in tumour (a), liver (b), lungs (c) and heart (d) was determined using plaque assay. 
Data shown is representative of mean plaque forming units per gram of tissue. There was a 
significant difference (*) in pfu/g of tissue in the tumour group between mice treated with 
reovirus alone and the sequenced combination (unpaired t-test;p=0.03). 
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Figure 10 Rapamycin does not affect the humoral response to reovirus at the dose of 
5mg/kg. The level of neutralising antibody in the serum of tumour bearing mice treated with 
either reovirus alone, or in concomitant or sequenced combination was determined. 
Unpaired student T –tests were carried out to compare reovirus NARA endpoint titre vs 
reovirus then rapamycin endpoint titre, also reovirus endpoint titre vs concomitant endpoint 
titre. These unpaired student T –tests showed no significant difference P= >0.1 
 
 
